Literature DB >> 17249380

Cyclooxygenase-2 and tumor biology.

Shigeru Kanaoka1, Tetsunari Takai, Ken-ichi Yoshida.   

Abstract

There is now substantial evidence for the role of cyclooxygenase (COX)-2 in causation and prevention of cancer. Selective COX-2 inhibitors (coxibs) were considered attractive candidate chemoprevention agents; however, concerns over the toxicity of systemic selective inhibition have cast some doubt on COX-2 inhibition as a safe chemoprevention strategy. COX-2 can serve as a potential biomarker of tumor evaluation including prognosis. This chapter describes proposed mechanisms for the role of COX-2 in carcinogenesis, proliferation, inhibition of apoptosis, promotion of angiogenesis, enhanced invasiveness, immune modulation, and increased mutagenesis. Critical discussions focus on the use of COX-2 as a biomarker in the evaluation of neoplasm. Our chapter demonstrates that "Fecal COX-2 Assay," a novel method to detect COX-2 messenger RNA (mRNA) in feces from subjects with colorectal neoplasms, is potentially useful for colorectal cancer screening.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17249380

Source DB:  PubMed          Journal:  Adv Clin Chem        ISSN: 0065-2423            Impact factor:   5.394


  7 in total

1.  Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer.

Authors:  Y Hamaya; K Yoshida; T Takai; M Ikuma; A Hishida; S Kanaoka
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

2.  Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4.

Authors:  Chao Xie; Bojian Liang; Ming Xue; Angela S P Lin; Alayna Loiselle; Edward M Schwarz; Robert E Guldberg; Regis J O'Keefe; Xinping Zhang
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

3.  Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.

Authors:  Elizabeth L Barry; Leah B Sansbury; Maria V Grau; Iqbal U Ali; Shirley Tsang; David J Munroe; Dennis J Ahnen; Robert S Sandler; Fred Saibil; Jiang Gui; Robert S Bresalier; Gail E McKeown-Eyssen; Carol Burke; John A Baron
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-15       Impact factor: 4.254

4.  Caveolin-1-mediated suppression of cyclooxygenase-2 via a beta-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression.

Authors:  Diego A Rodriguez; Julio C Tapia; Jaime G Fernandez; Vicente A Torres; Nicolas Muñoz; Daniela Galleguillos; Lisette Leyton; Andrew F G Quest
Journal:  Mol Biol Cell       Date:  2009-02-25       Impact factor: 4.138

5.  Utility of novel 2-furanones in synthesis of other heterocyclic compounds having anti-inflammatory activity with dual COX2/LOX inhibition.

Authors:  Rania H Abd El-Hameed; Shahenda Mahgoub; Hend M El-Shanbaky; Mosaad S Mohamed; Sahar A Ali
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

6.  Endoplasmic reticulum stress-induced resistance to doxorubicin is reversed by paeonol treatment in human hepatocellular carcinoma cells.

Authors:  Lulu Fan; Bing Song; Guoping Sun; Tai Ma; Fei Zhong; Wei Wei
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

7.  The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer.

Authors:  Min Kyu Kang; Won Park; Yoon-La Choi; Eun Yoon Cho; Geunghwan Ahn; Heerim Nam; Seung Jae Huh; Yong Chan Ahn; Do Hoon Lim; Dong Ryul Oh; Duk Soo Bae; Byoung Gie Kim
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.